Compare · BDX vs PETV
BDX vs PETV
Side-by-side comparison of Becton Dickinson and Company (BDX) and PetVivo Holdings Inc. (PETV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PETV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.58B, about 3516.9x PETV ($12.4M).
- BDX has been more active in the news (4 items in the past 4 weeks vs 3 for PETV).
- BDX has more recent analyst coverage (25 ratings vs 1 for PETV).
- Company
- Becton Dickinson and Company
- PetVivo Holdings Inc.
- Price
- $158.16-1.07%
- $1.02-4.67%
- Market cap
- $43.58B
- $12.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 1
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
PetVivo Holdings Inc.
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest PETV
- PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
- SEC Form 10-K filed by PetVivo Holdings Inc.
- PetVivo Reports Financial and Operational Results for Fiscal 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- PetVivo Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026
- PetVivo Holdings Announces Transformative Acquisition Of PiezoBioMembrane To Build a Leading Functional Biomaterials Platform
- Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
- PetVivo Holdings, Inc. to Present at the Life Sciences Investor Forum on June 24th
- PetVivo Holdings, Inc. to Host Virtual Investor Event